Forging New Paths in Neurodegenerative Drug Development
Aiming not only to treat neurodegenerative disease symptoms but to alter the disease’s progression.
Acurex’s platform and founding intellectual property are based on a Stanford University breakthrough discovery that enabled the identification of druggable targets for Parkinson’s disease. Acurex is supported by funding from Stanford University, the University of California, the Michael J. Fox Foundation for Parkinson’s Research, Parkinson’s UK, The Silverstein Foundation for Parkinson’s with GBA, and the National Institute on Aging.
Our proprietary platform allows us to pinpoint unique druggable targets that lead to detectable biomarker changes in neurological diseases.
Acurex’s lead drug candidate, CU-13001, is an oral, brain-penetrant small molecule designed to leverage our innovative approach to treating Parkinson’s Disease. This breakthrough therapy is part of our broader pipeline of early-stage neurology drug candidates.